Pharma companies showcase their R&D achievements
By Son, Hyung-Min | translator Kang, Shin-Kook
24.05.13 05:40:24
가나다라
0
ProGen, developing GLP-1·GIP-2 targeted obesity treatments…has proven effects in preclinical trials
Daewoong Therapeutics, to commercialize microneedle patch…has 'the advantage of room temperature storage'
▲ProGen’s CEO Jong Gyun-Kim
Pharmaceutical companies have disclosed the development outcomes of the obesity treatments, which have now become the trending R&D. As obesity treatments of the GLP-1 class, such as those of Novo Nordisk and Lilly, become blockbuster new drugs globally, the development of latecomers is on the rise. Major companies plan to develop the next-generation obesity treatments related to GLP-1/GLP-2 and microneedle.
At BIO KOREA 2024, held on May 8th at Coex, Seoul, the session titled ‘Advancements and Strategic Directions in the Diabetes-Obesity Treatment Market‘ was held. During the session, ProGen and Daewoong Therapeutics showcased their next-generation obesity treatments.
Global p
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)